Avoro Capital Advisors LLC Purchases 117,777 Shares of Krystal Biotech, Inc. $KRYS

Avoro Capital Advisors LLC increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,777,777 shares of the company’s stock after buying an additional 117,777 shares during the quarter. Krystal Biotech comprises 6.3% of Avoro Capital Advisors LLC’s portfolio, making the stock its 5th largest holding. Avoro Capital Advisors LLC owned about 9.58% of Krystal Biotech worth $490,361,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in shares of Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC grew its position in Krystal Biotech by 29.9% in the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after buying an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Krystal Biotech by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after buying an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new position in Krystal Biotech during the 1st quarter valued at about $218,000. Finally, Envestnet Asset Management Inc. raised its position in shares of Krystal Biotech by 21.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 15,116 shares of the company’s stock worth $2,078,000 after buying an additional 2,717 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. The Goldman Sachs Group boosted their target price on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Citigroup lifted their price target on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, Guggenheim boosted their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $326.25.

Krystal Biotech Trading Down 1.6%

Krystal Biotech stock opened at $247.26 on Friday. The company has a market capitalization of $7.23 billion, a P/E ratio of 36.10 and a beta of 0.49. The firm’s fifty day simple moving average is $270.50 and its 200-day simple moving average is $222.04. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The firm had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million. On average, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Dino A. Rossi sold 18,950 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total value of $4,953,719.50. Following the completion of the sale, the director directly owned 78,691 shares in the company, valued at approximately $20,570,614.31. The trade was a 19.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the sale, the insider directly owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. The trade was a 1.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 129,164 shares of company stock valued at $34,538,578 over the last 90 days. 13.70% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.